


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously presented) A compound of Formula (I)



or a pharmaceutically acceptable salt thereof, wherein:

R¹ is hydrogen;
 CN;
 halogen; or
 C₁₋₄ alkyl, optionally substituted with one or more fluoro;

R² is hydrogen;
 CN;
 halogen; or
 C₁₋₆ alkyl substituted with one or more fluoro;

R³ is hydrogen;
 C₁₋₄ alkyl; or
 C₃₋₆ cycloalkyl;

A is A¹, wherein A¹ is selected from the group consisting of:
 phenyl;
 naphthyl;

heterocycle containing up to 4 heteroatoms, which are the same or different and selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-, -N=, -N(O)= and -N(R⁴)-; and

heterobicycles containing up to 6 heteroatoms, which are the same or different and selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-, -N=, -N(O)= and -N(R⁴)-;

wherein A¹ is optionally substituted with one or independently from each other more of

A²;

A³;

halogen;

CN;

-N(R⁵R⁶);

-OH;

=O, where the ring is at least partially saturated;

C₃₋₆ cycloalkyl;

-COOR⁷; or

-CONR⁸R⁹;

-S(O)₂NR^{8a}R^{9a}

and wherein R⁴, R⁵, R⁶ are independently selected from the group consisting of R^{7a}, -C(O)-R^{7a}, -C(O)O-R^{7a}, -C(O)NR^{7a}R^{7b}, -S(O)₂NR^{7a}R^{7b}, and S(O)₂-R^{7a};

and wherein R⁷, R^{7a}, R^{7b}, R⁸, R^{8a}, R⁹, R^{9a} are independently hydrogen or C₁₋₄ alkyl, wherein each C₁₋₄ alkyl is optionally substituted with one or more substituents independently selected from the group consisting of -COOH; -OH; -NH₂; -NH-C₁₋₄ alkyl; -N(C₁₋₄ alkyl)₂; and C₃₋₆ cycloalkyl;

Optionally R⁴ is a bond to directly attach A to B;

A² is selected from the group consisting of A⁴, -O-A⁴ and -N(R¹⁰)-A⁴,

wherein A⁴ is phenyl or a heterocycle containing up to 4 heteroatoms, which are the same or different and selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-, -N=, -N(O)= and -N(R¹¹)-; wherein A⁴ is optionally substituted with one or independently from each other more of

fluoro;

chloro;

-N(R¹²R¹³)

C₁₋₄ alkyl or -O-C₁₋₄ alkyl, both optionally substituted with one or independently from each other more of fluoro or -N(R¹⁴R¹⁵);

and wherein R¹⁰, R¹², R¹³, R¹⁴, R¹⁵ are independently hydrogen or C₁₋₄ alkyl;

and wherein R¹¹ is selected from the group consisting of hydrogen, C₁₋₄ alkyl and -C(O)-C₁₋₄ alkyl;

A³ is selected from the group consisting of C₁₋₆ alkyl, -O-C₁₋₆ alkyl and -N(R¹⁶)-C₁₋₆ alkyl, wherein the C₁₋₆ alkyl group is optionally substituted with one or independently from each other more of

fluoro;

-N(R¹⁷R¹⁸);

A⁵;

and/or A³ is optionally interrupted with one or more oxygen;

and wherein R¹⁶, R¹⁷, R¹⁸ are independently hydrogen or C₁₋₄alkyl;

A⁵ is phenyl or a heterocycle containing up to 4 heteroatoms, which are the same or different and selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-, -N=, -N(O)= and -N(R¹⁹)-; wherein A⁵ is optionally substituted with one or independently from each other more of

fluoro;

chloro;

-N(R²⁰R²¹)

C₁₋₄ alkyl or -O-C₁₋₄ alkyl, both optionally substituted with one or independently from each other more of fluoro or -N(R²²R²³);

and wherein R¹⁹ is selected from the group consisting of hydrogen, C₁₋₄ alkyl

and -C(O)-C₁₋₄ alkyl;

and wherein R²⁰, R²¹, R²², R²³ are independently hydrogen or C₁₋₄ alkyl;

B is selected from the group consisting of -Y-Z-; -Y-Z-C(O)-; -Y-Z-O-C(O)-; -Y-Z-S(O)₂-; and -Y-Z-NH-C(O)- wherein

Y is a bond, -O-, -S-, -N(R²⁴)-, -N(R²⁵)-C(O)-, -C(O)-N(R²⁶)-, or -C(O)-;

Z is C₁₋₆ alkyl,

optionally interrupted with oxygen, sulfur or -N(R²⁷)-

and/or optionally substituted with one or independently from each other more of

halogen;

CN;

C₃₋₆ cycloalkyl;

-COOR²⁸;

-CON(R²⁹R³⁰)

and/or optionally one chain carbon forms part of a C₃₋₆ cycloalkyl;

and wherein R²⁴, R²⁵, R²⁶, R²⁷, R²⁸, R²⁹, R³⁰ are independently

hydrogen; or

C₁₋₄ alkyl, optionally substituted with -COOR³¹ or -CON(R³²R³³)

wherein R³¹, R³², R³³ are independently hydrogen or C₁₋₄ alkyl;

X is =C(R³⁴)- or =N-, wherein R³⁴ is

hydrogen;

C₁₋₆ alkyl, optionally substituted with one or more fluoro; or

-S(O)₂R³⁵, wherein R³⁵ is selected from the group consisting of X¹, C₁₋₆ alkyl,

and -C₁₋₆ alkyl-X¹; wherein R³⁵ is optionally substituted with one or

independently from each other more of

fluoro;

chloro;

C₁₋₄ alkyl; or

-O-C₁₋₄ alkyl;

X¹ is phenyl or heterocycle containing up to 4 heteroatoms, which are the same or different and selected from the group consisting of -O-, -S-, -S(O)-, -S(O)₂-, -N=, -N(O)= and -N(R³⁶)-; and wherein R³⁶ is selected from the group consisting of hydrogen, C₁₋₄ alkyl and -C(O)-C₁₋₄ alkyl;

G is -CH(R³⁷)-C(R³⁸R³⁹)-;

$-\text{CH}(\text{R}^{37})-\text{C}(\text{R}^{38}\text{R}^{39})-\text{C}(\text{R}^{40}\text{R}^{41})-$;

wherein R^{37} , R^{38} , R^{39} , R^{40} , R^{41} are independently

hydrogen;

C_{1-4} alkyl, optionally substituted with one or more fluoro;

C_{3-6} cycloalkyl, optionally substituted with one or more fluoro;

or R^{38} and R^{39} or R^{40} and R^{41} form together C_{3-6} cycloalkyl, optionally

substituted with one or more fluoro, $-\text{OH}$, C_{1-4} alkyl;

or R^{37} and R^{38} or R^{38} and R^{40} form together C_{3-6} cycloalkyl, optionally

substituted with one or more fluoro, $-\text{OH}$, C_{1-4} alkyl;

D is C_{1-6} alkyl,

optionally interrupted with oxygen, sulfur or $-\text{N}(\text{R}^{42})-$

and/or optionally substituted with halogen, CN, C_{3-6} cycloalkyl;

and/or optionally one chain carbon or two vicinal carbons form part of a C_{3-6} cycloalkyl,

wherein R^{42} is selected from the group consisting of hydrogen, C_{1-4} alkyl, C_{3-6} cycloalkyl

and $-\text{C}(\text{O})-\text{C}_{1-4}$ alkyl;

E is E^1 , wherein E^1 is selected from the group consisting of

phenyl;

naphthyl;

heterocycle containing up to 4 heteroatoms, which are the same or different and

selected from the group consisting of $-\text{O}-$, $-\text{S}-$, $-\text{S}(\text{O})-$, $-\text{S}(\text{O}_2)-$, $-\text{N}=\text{}$,

$-\text{N}(\text{O})=\text{}$ and $-\text{N}(\text{R}^{43})-$; and

heterobicycle containing up to 6 heteroatoms, which are the same or different

and selected from the group consisting of $-\text{O}-$, $-\text{S}-$, $-\text{S}(\text{O})-$, $-\text{S}(\text{O}_2)-$, $-\text{N}=\text{}$,

$-\text{N}(\text{O})=\text{}$ and $-\text{N}(\text{R}^{44})-$;

wherein E^1 is optionally substituted with one or independently from each other more of

E^2 ;

E^3 ;

halogen;

CN;

$-\text{N}(\text{R}^{45}\text{R}^{46})$;

$-\text{OH}$;

=O, where the ring is at least partially saturated;

C₃₋₆ cycloalkyl;

-COOR⁴⁷; or

-CONR⁴⁸R⁴⁹;

-S(O)₂NR^{48a}R^{49a};

and wherein R⁴³, R⁴⁴, R⁴⁵, R⁴⁶ are independently selected from the group consisting of hydrogen;

C₁₋₄ alkyl optionally substituted with -OH;

and -C(O)-C₁₋₄ alkyl optionally substituted with -OH;

and wherein R⁴⁷, R⁴⁸, R^{48a}, R⁴⁹, R^{49a} are independently hydrogen or C₁₋₄ alkyl, optionally substituted with -OH;

E² is selected from the group consisting of E⁴, -C(O)-E⁴, -O-E⁴ and -N(R⁵⁰)-E⁴,

wherein E⁴ is phenyl or heterocycle containing up to 4 heteroatoms, which are the same or different and selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-, -N=, -N(O)= and -N(R⁵¹)-; wherein E⁴ is optionally substituted with one or independently from each other more of

fluoro;

chloro;

cyano;

=O, where the ring is at least partially saturated;

-N(R⁵²R⁵³);

C₁₋₄ alkyl; or

-O-C₁₋₄ alkyl;

and wherein R⁵⁰, R⁵², R⁵³ are independently hydrogen or C₁₋₄ alkyl, optionally substituted with -OH;

and wherein R⁵¹ is selected from the group consisting of hydrogen;

C₁₋₄ alkyl, optionally substituted with -OH; and

-C(O)-C₁₋₄ alkyl, optionally substituted with -OH;

E^3 is selected from the group consisting of C_{1-6} alkyl, $-O-C_{1-6}$ alkyl, $-N(R^{54})-C_{1-6}$ alkyl, wherein E^3 is optionally substituted with one or independently from each other more of

fluoro;

$-N(R^{55}R^{56})$;

E^5 ;

and/or E^3 is optionally interrupted with one or more oxygen;

and wherein R^{54} , R^{55} , R^{56} are independently hydrogen or C_{1-4} alkyl, optionally substituted with $-OH$;

E^5 is phenyl or heterocycle containing up to 4 heteroatoms, which are the same or different and selected from the group consisting of $-O-$, $-S-$, $-S(O)-$, $-S(O_2)-$, $-N=$, $-N(O)=$ and $-N(R^{57})-$; wherein E^5 is optionally substituted with one or independently from each other more of

fluoro;

chloro;

cyano;

$=O$, where the ring is at least partially saturated;

$-N(R^{58}R^{59})$;

C_{1-4} alkyl or

$-O-C_{1-4}$ alkyl;


and wherein R^{57} is independently selected from the group consisting of hydrogen;

C_{1-4} alkyl, optionally substituted with $-OH$; and

$-C(O)-C_{1-4}$ alkyl, optionally substituted with $-OH$;

and wherein R^{58} , R^{59} are independently hydrogen or C_{1-4} alkyl, optionally substituted with $-OH$.

2. (Previously presented) A compound of Formula (I)



or a pharmaceutically acceptable salt thereof, wherein:

R¹ is hydrogen;
CN;
halogen; or
C₁₋₄ alkyl, optionally substituted with one or more fluoro;

R² is hydrogen;
halogen;
CN;
C₁₋₆ alkyl, optionally substituted with one or more fluoro;
C₃₋₆ cycloalkyl; or
O-C₁₋₄ alkyl;

R³ is hydrogen;
C₁₋₄ alkyl; or
C₃₋₆ cycloalkyl;

A is A¹, wherein A¹ is selected from the group consisting of:
phenyl;
naphthyl;
heterocycle containing up to 4 heteroatoms, which are the same or different and
selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-, -N=,
-N(O)= and -N(R⁴)-; and
heterobicycles containing up to 6 heteroatoms, which are the same or different
and selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-, -N=,
-N(O)= and -N(R⁴)-;
wherein A¹ is optionally substituted with one or independently from each other
more of
A²;
A³;
halogen;

CN;
-N(R⁵R⁶);
-OH;
=O, where the ring is at least partially saturated;
C₃₋₆ cycloalkyl;
-COOR⁷; or
-CONR⁸R⁹;
-S(O)₂NR^{8a}R^{9a}

and wherein R⁴, R⁵, R⁶ are independently selected from the group consisting of R^{7a},
-C(O)-R^{7a}, -C(O)O-R^{7a}, -C(O)NR^{7a}R^{7b}, -S(O)₂NR^{7a}R^{7b}, and S(O)₂-R^{7a};

and wherein R⁷, R^{7a}, R^{7b}, R⁸, R^{8a}, R⁹, R^{9a} are independently hydrogen or C₁₋₄ alkyl,
wherein each C₁₋₄ alkyl is optionally substituted with one or more substituents
independently selected from the group consisting of -COOH; -OH; -NH₂;
-NH-C₁₋₄ alkyl; -N(C₁₋₄ alkyl)₂; and C₃₋₆ cycloalkyl;

Optionally R⁴ is a bond to directly attach A to B;

A² is selected from the group consisting of A⁴, -O-A⁴ and -N(R¹⁰)-A⁴,

wherein A⁴ is phenyl or a heterocycle containing up to 4 heteroatoms, which are the
same or different and selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-,
-N=, -N(O)= and -N(R¹¹)-; wherein A⁴ is optionally substituted with one or independently
from each other more of

fluoro;
chloro;
-N(R¹²R¹³)

C₁₋₄ alkyl or -O-C₁₋₄ alkyl, both optionally substituted with one or independently
from each other more of fluoro or -N(R¹⁴R¹⁵);

and wherein R¹⁰, R¹², R¹³, R¹⁴, R¹⁵ are independently hydrogen or C₁₋₄ alkyl;

and wherein R¹¹ is selected from the group consisting of hydrogen, C₁₋₄ alkyl
and -C(O)-C₁₋₄ alkyl;

A³ is selected from the group consisting of C₁₋₆ alkyl, -O-C₁₋₆ alkyl and -N(R¹⁶)-C₁₋₆ alkyl, wherein the C₁₋₆ alkyl group is optionally substituted with one or independently from each other more of

fluoro;

-N(R¹⁷R¹⁸);

A⁵;

and/or A³ is optionally interrupted with one or more oxygen;

and wherein R¹⁶, R¹⁷, R¹⁸ are independently hydrogen or C₁₋₄alkyl;

A⁵ is phenyl or a heterocycle containing up to 4 heteroatoms, which are the same or different and selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-, -N=, -N(O)= and -N(R¹⁹)-; wherein A⁵ is optionally substituted with one or independently from each other more of

fluoro;

chloro;

-N(R²⁰R²¹)

C₁₋₄ alkyl or -O-C₁₋₄ alkyl, both optionally substituted with one or independently from each other more of fluoro or -N(R²²R²³);

and wherein R¹⁹ is selected from the group consisting of hydrogen, C₁₋₄ alkyl

and -C(O)-C₁₋₄ alkyl;

and wherein R²⁰, R²¹, R²², R²³ are independently hydrogen or C₁₋₄ alkyl;

B is selected from the group consisting of -Y-Z-, -Y-Z-C(O)-; -Y-Z-O-C(O)-; -Y-Z-S(O)₂-; and -Y-Z-NH-C(O)- wherein

Y is a bond, -O-, -S-, -N(R²⁴)-, -N(R²⁵)-C(O)-, -C(O)-N(R²⁶)-, or -C(O)-;

Z is C₁₋₆ alkyl,

optionally interrupted with oxygen, sulfur or -N(R²⁷)-

and/or optionally substituted with one or independently from each other more of

halogen;

CN;

C₃₋₆ cycloalkyl;

-COOR²⁸;

-CON(R²⁹R³⁰)

and/or optionally one chain carbon forms part of a C₃₋₆ cycloalkyl;
and wherein R²⁴, R²⁵, R²⁶, R²⁷, R²⁸, R²⁹, R³⁰ are independently
hydrogen; or
C₁₋₄ alkyl, optionally substituted with -COOR³¹ or -CON(R³²R³³)
wherein R³¹, R³², R³³ are independently hydrogen or
C₁₋₄ alkyl;

X is =C(R³⁴)- or =N-, wherein R³⁴ is

hydrogen;

C₁₋₆ alkyl, optionally substituted with one or more fluoro; or

-S(O)₂R³⁵, wherein R³⁵ is selected from the group consisting of X¹, C₁₋₆ alkyl,

and -C₁₋₆ alkyl-X¹; wherein R³⁵ is optionally substituted with one or

independently from each other more of

fluoro;

chloro;

C₁₋₄ alkyl; or

-O-C₁₋₄ alkyl;

X¹ is phenyl or heterocycle containing up to 4 heteroatoms, which are the same or different and
selected from the group consisting of -O-, -S-, -S(O)-, -S(O)₂-, -N=, -N(O)= and -N(R³⁶)-; and
wherein R³⁶ is selected from the group consisting of hydrogen, C₁₋₄ alkyl and -C(O)-C₁₋₄ alkyl;

G is -CH(R³⁷)-C(R³⁸R³⁹)-;

-CH(R³⁷)-C(R³⁸R³⁹)-C(R⁴⁰R⁴¹)-;

wherein R³⁷, R³⁸, R³⁹, R⁴⁰, R⁴¹ are independently

hydrogen;

C₁₋₄ alkyl, optionally substituted with one or more fluoro;

C₃₋₆ cycloalkyl, optionally substituted with one or more fluoro;

or R³⁸ and R³⁹ or R⁴⁰ and R⁴¹ form together C₃₋₆ cycloalkyl, optionally

substituted with one or more fluoro, -OH, C₁₋₄ alkyl;

or R³⁷ and R³⁸ or R³⁸ and R⁴⁰ form together C₃₋₆ cycloalkyl, optionally

substituted with one or more fluoro, -OH, C₁₋₄ alkyl;

D is C₁₋₆ alkyl,
optionally interrupted with oxygen, sulfur or -N(R⁴²)-
and/or optionally substituted with halogen, CN, C₃₋₆ cycloalkyl;
and/or optionally one chain carbon or two vicinal carbons form part of a C₃₋₆ cycloalkyl,
wherein R⁴² is selected from the group consisting of hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl
and -C(O)-C₁₋₄ alkyl;

E is E¹, wherein E¹ is selected from the group consisting of
naphthyl;
non-aromatic heterocycle containing up to 4 heteroatoms, which are the same or
different and

selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-, -N=,
-N(O)= and -N(R⁴³)-; and

heterobicycle containing up to 6 heteroatoms, which are the same or different

and selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-, -N=,
-N(O)= and -N(R⁴⁴)-;

wherein E¹ is optionally substituted with one or independently from each other more of

E²;

E³;

halogen;

CN;

-N(R⁴⁵R⁴⁶);

-OH;

=O, where the ring is at least partially saturated;

C₃₋₆ cycloalkyl;

-COOR⁴⁷; or

-CONR⁴⁸R⁴⁹;

-S(O)₂NR^{48a}R^{49a};

and wherein R⁴³, R⁴⁴, R⁴⁵, R⁴⁶ are independently selected from the group consisting of
hydrogen;

C₁₋₄ alkyl optionally substituted with -OH;

and -C(O)-C₁₋₄ alkyl optionally substituted with -OH;

and wherein R^{47} , R^{48} , R^{48a} , R^{49} , R^{49a} are independently hydrogen or C_{1-4} alkyl, optionally substituted with -OH;

E^2 is selected from the group consisting of E^4 , $-C(O)-E^4$, $-O-E^4$ and $-N(R^{50})-E^4$,

wherein E^4 is phenyl or heterocycle containing up to 4 heteroatoms, which are the same or different and selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-, -N=, -N(O)= and $-N(R^{51})-$; wherein E^4 is optionally substituted with one or independently from each other more of

fluoro;

chloro;

cyano;

=O, where the ring is at least partially saturated;

$-N(R^{52}R^{53})$;

C_{1-4} alkyl; or

$-O-C_{1-4}$ alkyl;

and wherein R^{50} , R^{52} , R^{53} are independently hydrogen or C_{1-4} alkyl, optionally substituted with -OH;

and wherein R^{51} is selected from the group consisting of

hydrogen;

C_{1-4} alkyl, optionally substituted with -OH; and

$-C(O)-C_{1-4}$ alkyl, optionally substituted with -OH;

E^3 is selected from the group consisting of C_{1-6} alkyl, $-O-C_{1-6}$ alkyl; $-N(R^{54})-C_{1-6}$ alkyl, wherein E^3 is optionally substituted with one or independently from each other more of

fluoro;

$-N(R^{55}R^{56})$;

E^5 ;

and/or E^3 is optionally interrupted with one or more oxygen;

and wherein R^{54} , R^{55} , R^{56} are independently hydrogen or C_{1-4} alkyl, optionally substituted with -OH;

E⁵ is phenyl or heterocycle containing up to 4 heteroatoms, which are the same or different and selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-, -N=, -N(O)= and -N(R⁵⁷)-; wherein E⁵ is optionally substituted with one or independently from each other more of

fluoro;

chloro;

cyano;

=O, where the ring is at least partially saturated;

-N(R⁵⁸R⁵⁹);

C₁₋₄ alkyl or

-O-C₁₋₄ alkyl;


and wherein R⁵⁷ is independently selected from the group consisting of hydrogen;

C₁₋₄ alkyl, optionally substituted with -OH; and

-C(O)-C₁₋₄ alkyl, optionally substituted with -OH;

and wherein R⁵⁸, R⁵⁹ are independently hydrogen or C₁₋₄ alkyl, optionally substituted with -OH.

3. (Previously presented) A compound of Formula (I)



or a pharmaceutically acceptable salt thereof, wherein:

R¹ is hydrogen;

CN;

halogen; or

C₁₋₄ alkyl, optionally substituted with one or more fluoro;

R² is hydrogen;

CN;

halogen;

C₁₋₆ alkyl, optionally substituted with one or more fluoro;

C₃₋₆ cycloalkyl; or

O-C₁₋₄ alkyl;

R³ is hydrogen;

C₁₋₄ alkyl; or

C₃₋₆ cycloalkyl;

A is A¹, wherein A¹ is selected from the group consisting of:

naphthyl;

heterocycle containing up to 4 heteroatoms, which are the same or different and

selected from the group consisting of -S(O)-, -S(O₂)- and -N(O)=; and

heterobicycles containing up to 6 heteroatoms, which are the same or different

and selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-, -N=, -N(O)= and -N(R⁴)-;

wherein A¹ is optionally substituted with one or independently from each other more of

A²;

A³;

halogen;

CN;

-N(R⁵R⁶);

-OH;

=O, where the ring is at least partially saturated;

C₃₋₆ cycloalkyl;

-COOR⁷; or

-CONR⁸R⁹;

-S(O)₂NR^{8a}R^{9a}

and wherein R⁴, R⁵, R⁶ are independently selected from the group consisting of R^{7a}, -C(O)-R^{7a}, -C(O)O-R^{7a}, -C(O)NR^{7a}R^{7b}, -S(O)₂NR^{7a}R^{7b}, and S(O)₂-R^{7a};

and wherein R⁷, R^{7a}, R^{7b}, R⁸, R^{8a}, R⁹, R^{9a} are independently hydrogen or C₁₋₄ alkyl, wherein each C₁₋₄ alkyl is optionally substituted with one or more substituents

independently selected from the group consisting of -COOH; -OH; -NH₂; -NH-C₁₋₄ alkyl; -N(C₁₋₄ alkyl)₂; and C₃₋₆ cycloalkyl;

Optionally R⁴ is a bond to directly attach A to B;

A² is selected from the group consisting of A⁴, -O-A⁴ and -N(R¹⁰)-A⁴,

wherein A⁴ is phenyl or a heterocycle containing up to 4 heteroatoms, which are the same or different and selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-, -N=, -N(O)= and -N(R¹¹)-; wherein A⁴ is optionally substituted with one or independently from each other more of

fluoro;

chloro;

-N(R¹²R¹³)

C₁₋₄ alkyl or -O-C₁₋₄ alkyl, both optionally substituted with one or independently from each other more of fluoro or -N(R¹⁴R¹⁵);

and wherein R¹⁰, R¹², R¹³, R¹⁴, R¹⁵ are independently hydrogen or C₁₋₄ alkyl;

and wherein R¹¹ is selected from the group consisting of hydrogen, C₁₋₄ alkyl and -C(O)-C₁₋₄ alkyl;

A³ is selected from the group consisting of C₁₋₆ alkyl, -O-C₁₋₆ alkyl and -N(R¹⁶)-C₁₋₆ alkyl, wherein the C₁₋₆ alkyl group is optionally substituted with one or independently from each other more of

fluoro;

-N(R¹⁷R¹⁸);

A⁵;

and/or A³ is optionally interrupted with one or more oxygen;

and wherein R¹⁶, R¹⁷, R¹⁸ are independently hydrogen or C₁₋₄alkyl;

A⁵ is phenyl or a heterocycle containing up to 4 heteroatoms, which are the same or different and selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-, -N=, -N(O)= and -N(R¹⁹)-; wherein A⁵ is optionally substituted with one or independently from each other more of

fluoro;

chloro;

$-N(R^{20}R^{21})$

C_{1-4} alkyl or $-O-C_{1-4}$ alkyl, both optionally substituted with one or independently from each other more of fluoro or $-N(R^{22}R^{23})$;

and wherein R^{19} is selected from the group consisting of hydrogen, C_{1-4} alkyl and $-C(O)-C_{1-4}$ alkyl;

and wherein R^{20} , R^{21} , R^{22} , R^{23} are independently hydrogen or C_{1-4} alkyl;

B is selected from the group consisting of $-Y-Z-$; $-Y-Z-C(O)-$; $-Y-Z-O-C(O)-$; $-Y-Z-S(O)_2-$; and $-Y-Z-NH-C(O)-$ wherein

Y is a bond, $-O-$, $-S-$, $-N(R^{24})-$, $-N(R^{25})-C(O)-$, $-C(O)-N(R^{26})-$, or $-C(O)-$;

Z is C_{1-6} alkyl,

optionally interrupted with oxygen, sulfur or $-N(R^{27})-$

and/or optionally substituted with one or independently from each other more of

halogen;

CN;

C_{3-6} cycloalkyl;

$-COOR^{28}$;

$-CON(R^{29}R^{30})$

and/or optionally one chain carbon forms part of a C_{3-6} cycloalkyl;

and wherein R^{24} , R^{25} , R^{26} , R^{27} , R^{28} , R^{29} , R^{30} are independently

hydrogen; or

C_{1-4} alkyl, optionally substituted with $-COOR^{31}$ or $-CON(R^{32}R^{33})$

wherein R^{31} , R^{32} , R^{33} are independently hydrogen or C_{1-4} alkyl;

X is $=C(R^{34})-$ or $=N-$, wherein R^{34} is

hydrogen;

C_{1-6} alkyl, optionally substituted with one or more fluoro; or

$-S(O)_2R^{35}$, wherein R^{35} is selected from the group consisting of X^1 , C_{1-6} alkyl,

and $-C_{1-6}$ alkyl- X^1 ; wherein R^{35} is optionally substituted with one or

independently from each other more of

fluoro;

chloro;

C₁₋₄ alkyl; or

-O-C₁₋₄ alkyl;

X¹ is phenyl or heterocycle containing up to 4 heteroatoms, which are the same or different and selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-, -N=, -N(O)= and -N(R³⁶)-; and wherein R³⁶ is selected from the group consisting of hydrogen, C₁₋₄ alkyl and -C(O)-C₁₋₄ alkyl;

G is -CH(R³⁷)-C(R³⁸R³⁹)-;

-CH(R³⁷)-C(R³⁸R³⁹)-C(R⁴⁰R⁴¹)-;

wherein R³⁷, R³⁸, R³⁹, R⁴⁰, R⁴¹ are independently

hydrogen;

C₁₋₄ alkyl, optionally substituted with one or more fluoro;

C₃₋₆ cycloalkyl, optionally substituted with one or more fluoro;

or R³⁸ and R³⁹ or R⁴⁰ and R⁴¹ form together C₃₋₆ cycloalkyl, optionally

substituted with one or more fluoro, -OH, C₁₋₄ alkyl;

or R³⁷ and R³⁸ or R³⁸ and R⁴⁰ form together C₃₋₆ cycloalkyl, optionally

substituted with one or more fluoro, -OH, C₁₋₄ alkyl;

D is C₁₋₆ alkyl,

optionally interrupted with oxygen, sulfur or -N(R⁴²)-

and/or optionally substituted with halogen, CN, C₃₋₆ cycloalkyl;

and/or optionally one chain carbon or two vicinal carbons form part of a C₃₋₆ cycloalkyl,

wherein R⁴² is selected from the group consisting of hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl

and -C(O)-C₁₋₄ alkyl;

E is E¹, wherein E¹ is selected from the group consisting of

phenyl;

naphthyl;

heterocycle containing up to 4 heteroatoms, which are the same or different and

selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-, -N=, -N(O)= and -

N(R⁴³)-; and

heterobicycle containing up to 6 heteroatoms, which are the same or different

and selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-, -N=, -N(O)= and -N(R⁴⁴)-;

wherein E¹ is optionally substituted with one or independently from each other more of

E²;

E³;

halogen;

CN;

-N(R⁴⁵R⁴⁶);

-OH;

=O, where the ring is at least partially saturated;

C₃₋₆ cycloalkyl;

-COOR⁴⁷; or

-CONR⁴⁸R⁴⁹;

-S(O)₂NR^{48a}R^{49a};

and wherein R⁴³, R⁴⁴, R⁴⁵, R⁴⁶ are independently selected from the group consisting of hydrogen;

C₁₋₄ alkyl optionally substituted with -OH;

and -C(O)-C₁₋₄ alkyl optionally substituted with -OH;

and wherein R⁴⁷, R⁴⁸, R^{48a}, R⁴⁹, R^{49a} are independently hydrogen or C₁₋₄ alkyl, optionally substituted with -OH;

E² is selected from the group consisting of E⁴, -C(O)-E⁴, -O-E⁴ and -N(R⁵⁰)-E⁴,

wherein E⁴ is phenyl or heterocycle containing up to 4 heteroatoms, which are the same or different and selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-, -N=, -N(O)= and -N(R⁵¹)-; wherein E⁴ is optionally substituted with one or independently from each other more of

fluoro;

chloro;

cyano;

=O, where the ring is at least partially saturated;

-N(R⁵²R⁵³);

C₁₋₄ alkyl; or

-O-C₁₋₄ alkyl;

and wherein R^{50} , R^{52} , R^{53} are independently hydrogen or C_{1-4} alkyl, optionally substituted with -OH;

and wherein R^{51} is selected from the group consisting of
hydrogen;
 C_{1-4} alkyl, optionally substituted with -OH; and
-C(O)- C_{1-4} alkyl, optionally substituted with -OH;

E^3 is selected from the group consisting of C_{1-6} alkyl, -O- C_{1-6} alkyl; -N(R^{54})- C_{1-6} alkyl, wherein E^3 is optionally substituted with one or independently from each other more of

fluoro;
-N(R^{55} R^{56});
 E^5 ;

and/or E^3 is optionally interrupted with one or more oxygen;

and wherein R^{54} , R^{55} , R^{56} are independently hydrogen or C_{1-4} alkyl, optionally substituted with -OH;

E^5 is phenyl or heterocycle containing up to 4 heteroatoms, which are the same or different and selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-, -N=, -N(O)= and -N(R^{57})-; wherein E^5 is optionally substituted with one or independently from each other more of

fluoro;
chloro;
cyano;
=O, where the ring is at least partially saturated;
-N(R^{58} R^{59});
 C_{1-4} alkyl or
-O- C_{1-4} alkyl;

and wherein R^{57} is independently selected from the group consisting of hydrogen;
 C_{1-4} alkyl, optionally substituted with -OH; and
-C(O)- C_{1-4} alkyl, optionally substituted with -OH;

and wherein R^{58} , R^{59} are independently hydrogen or C_{1-4} alkyl, optionally substituted with -OH.

4. (Previously presented) The compound of claim 1, wherein R^1 is hydrogen.
5. (Previously presented) The compound of claim 1, wherein R^2 is hydrogen, chloro, $-CH_3$, $-CH_2-CH_3$, $-CH_2-CH_2-CH_3$, $-CH_2-CH_2-CH_2-CH_3$, $-CH_2F$, $-CHF_2$ or $-CN$.
6. (Previously presented) The compound of claim 1, wherein R^3 is hydrogen.
7. (Previously presented) The compound of claim 1, wherein A^1 is phenyl or heterocycle containing up to 4 heteroatoms, which are the same or different and selected from the group consisting of $-O-$, $-S-$, $-S(O)-$, $-S(O)_2-$, $-N=$, $-N(O)=$ and $-N(R^4)-$, wherein R^4 has the meaning as indicated in claim 1.
8. (Original) A compound according to claim 7, wherein A^1 is selected from the group consisting of phenyl, pyridine, pyridine-N oxide, piperidine, morpholine, and pyrrolidine.
9. (Previously presented) The compound of claim 1, wherein R^4 is a bond, $-COOC_{1-4}$ alkyl, methyl, ethyl, 2-hydroxyethyl, $-COOH$, $-CH_2-COOH$, $-CH_2-COO-C_{1-4}$ alkyl or cyclopropylmethyl and wherein A^1 is optionally substituted with up to 4 F.
10. (Previously presented) The compound of claim 1, wherein B is $-Y-Z-$.
11. (Previously presented) The compound of claim 1, wherein Y is a bond, $-O-$, $-NH-$, $-S(O)_2-$ or $-C(O)-$.
12. (Previously presented) The compound of claim 1, wherein Z is $-C(R^{60}R^{61})-$ or $-C(R^{60}R^{61})-C(R^{62}R^{63})-$, wherein
 - R^{60} , R^{61} , R^{62} , R^{63} are independently hydrogen, $-C(O)NH_2$, $-COOH$, $-CH_2-COOH$, $-CH_2-C(O)NH_2$, fluoro, methyl, cyclopropyl or
 - R^{60} and R^{61} form a cyclopropyl ring or
 - R^{62} and R^{63} form a cyclopropyl ring or
 - R^{60} and R^{62} form a cyclopropyl or cyclobutyl ring.

13. (Original) A compound according to claim 12, wherein R^{60} , R^{61} , R^{62} , R^{63} are independently hydrogen, fluoro or $-C(O)NH_2$.

14. (Previously presented) The compound of claim 1, wherein X is $=N-$.

15. (Previously presented) The compound of claim 1, wherein G is $-CH(R^{64})-C(R^{65}R^{66})-$; wherein R^{64} , R^{65} , R^{66} are independently hydrogen, F, methyl, $-CH_2F$, $-CHF_2$, CF_3 or cyclopropyl or R^{65} , R^{66} form together cyclopropyl.

16. (Previously presented) The compound of claim 1, wherein G is $-CH_2-CH_2-$.


17. (Previously presented) The compound of claim 1, wherein D is $-CH_2-$, $-CF_2-$, $-CH(CH_3)-$, $-C(CH_3)_2-$ or D^1-D^2 , where D^1 and D^2 are independently $-CH_2-$, $-CF_2-$, $-CH(CH_3)-$ or $-C(CH_3)_2-$ and wherein D^2 is optionally $-CH_2-NH-$.

18. (Original) A compound according to claim 17, wherein D is $-CH_2-$, $-CH(CH_3)-$, $-CH_2-CH_2-$, $-CH_2-CF_2$ or $-CH_2-CH_2-NH-$.

19. (Previously presented) The compound of claim 1, wherein $-E$ is selected from the group consisting of phenyl; heterocycle containing up to three heteroatoms, which are the same or different and selected from the group consisting of $-O-$, $-N=$, $-N(O)-$ and $-NH-$; and heterobicycle containing up to three heteroatoms, which are the same or different and selected from the group consisting of $-O-$, $-N=$, and $-NH-$; and wherein E is optionally substituted with up to two substituents which are the same or different and selected from the group consisting of CN, F, Cl, C_{1-4} alkyl, OH, $O-C_{1-4}$ alkyl, NH_2 , $NH-C_{1-4}$ alkyl, $N(C_{1-4} \text{ alkyl})_2$, $C(O)NH_2$, $C(O)NH-C_{1-4}$ alkyl, and $C(O)N(C_{1-4} \text{ alkyl})_2$, wherein each C_{1-4} alkyl is optionally substituted with one or more substituents independently selected from OH and F.

20. (Original) A compound according to claim 19, wherein $-E$ is phenyl, pyridine, benzimidazole, indazole, quinoline, isoquinoline, pyridine-(N)-oxide, benzothiophene, indole, azaindole, benzofuran, benzisoxazole, benzoxazole, benzothiazole.

21. (Previously presented) The compound of claim 1, wherein -E is selected from the group consisting of



wherein

T and V are independently =CH-, =CR⁷¹-, =N- or =N(O)-;

U is -NH-, -NR⁷²-, -O-, or -S-, wherein

R⁶⁷, R⁶⁸, R⁶⁹, R⁷⁰, R⁷¹ are independently selected from the group consisting of
hydrogen;

C₃₋₆ cycloalkyl;

E⁶;

E^7 ;
halogen;
CN;
 $-N(R^{73}R^{74})$;
-OH; and
 $-COOR^{75}$ or $-C(O)NR^{76}R^{77}$;

and wherein R^{72} , R^{73} , R^{74} , R^{75} , R^{76} , R^{77} are independently
hydrogen;
 C_{1-4} alkyl; or
 $-C(O)-C_{1-4}$ alkyl;

E^6 is selected from the group consisting of C_{1-6} alkyl; $-O-C_{1-6}$ alkyl; and
 $-N(R^{78})-C_{1-6}$ alkyl, wherein the C_{1-6} alkyl group is optionally substituted with one or more of

halogen;

CN;

$-N(R^{79}R^{80})$;

phenyl, optionally substituted with chloro;

heterocycle containing up to 4 heteroatoms, which are the same or different and
selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-, -N=, -N(O)= and
 $-N(R^{81})-$, optionally substituted with chloro;

and/or E^6 is optionally interrupted by one or more of oxygen;


and wherein R^{78} , R^{79} , R^{80} , R^{81} are independently hydrogen, C_{1-4} alkyl;


E^7 is selected from the group consisting of E^8 ; $-O-E^8$; $-N(R^{82})-E^8$; and $-C(O)-E^8$, wherein E^8 is
phenyl or heterocycle containing up to 4 heteroatoms, which are the same or different and
selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-, -N=, -N(O)= and $-N(R^{83})-$; and
wherein E^8 is optionally substituted with chloro or $-N(R^{84}R^{85})$;














and wherein R^{82} , R^{83} , R^{84} , R^{85} are independently hydrogen or C_{1-4} alkyl.


22. (Original) A compound according to claim 21, wherein R^{67} , R^{68} , R^{69} , R^{70} , R^{71} are
independently selected from the group consisting of hydrogen, fluoro, chloro, cyano, phenyl,
chlorophenyl, methyl, methoxy, amino, monomethyl amino, dimethyl amino, pyrrolyl, diazoly,
triazoly, and tetrazoly.













23. (Original) A compound selected from the group consisting of:

































24. (Canceled)

25. (Previously presented) A pharmaceutical composition comprising a compound or a mixture of compounds or a pharmaceutically acceptable salt thereof according to claim 1 together with a pharmaceutically acceptable carrier.

26. (Canceled)

27. (Previously presented) The pharmaceutical composition according to claim 25, additionally comprising one or more known anticoagulants.

28. (Canceled)

29. (Canceled)

30. (Previously presented) A method for the treatment or prophylaxis of thromboembolism, thrombosis, arteriosclerosis, unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, or reocclusion or restenosis of

recanalized vessels, comprising administering to a patient a composition comprising the compound of claim 1.

31. (Canceled)

32. (Canceled)

33. (Previously presented) A method of treating a patient in need of an anticoagulant or thrombin inhibitor comprising administering a composition comprising the compound of claim 1 to said patient.

34. (New) The compound of claim 2, wherein R^1 is hydrogen.

35. (New) The compound of claim 2, wherein R^2 is hydrogen, chloro, $-CH_3$, $-CH_2-CH_3$, $-CH_2-CH_2-CH_3$, $-CH_2F$, $-CHF_2$ or $-CN$.

36. (New) The compound of claim 2, wherein R^3 is hydrogen.

37. (New) The compound of claim 2, wherein A^1 is phenyl or heterocycle containing up to 4 heteroatoms, which are the same or different and selected from the group consisting of $-O-$, $-S-$, $-S(O)-$, $-S(O)_2-$, $-N=$, $-N(O)=$ and $-N(R^4)-$, wherein R^4 has the meaning as indicated in claim 2.

38. (New) The compound according to claim 37, wherein A^1 is selected from the group consisting of phenyl, pyridine, pyridine-N oxide, piperidine, morpholine, and pyrrolidine.

39. (New) The compound of claim 2, wherein R^4 is a bond, $-COOC_{1-4}$ alkyl, methyl, ethyl, 2-hydroxyethyl, $-COOH$, $-CH_2-COOH$, $-CH_2-COO-C_{1-4}$ alkyl or cyclopropylmethyl and wherein A^1 is optionally substituted with up to 4 F.

40. (New) The compound of claim 2, wherein B is $-Y-Z-$.

41. (New) The compound of claim 2, wherein Y is a bond, $-O-$, $-NH-$, $-S(O)_2-$ or $-C(O)-$.

42. (New) The compound of claim 2, wherein Z is $-C(R^{60}R^{61})-$ or $-C(R^{60}R^{61})-C(R^{62}R^{63})-$, wherein

R^{60} , R^{61} , R^{62} , R^{63} are independently hydrogen, $-C(O)NH_2$, $-COOH$, $-CH_2COOH$, $-CH_2C(O)NH_2$, fluoro, methyl, cyclopropyl or
 R^{60} and R^{61} form a cyclopropyl ring or
 R^{62} and R^{63} form a cyclopropyl ring or
 R^{60} and R^{62} form a cyclopropyl or cyclobutyl ring.

43. (New) The compound according to claim 42, wherein R^{60} , R^{61} , R^{62} , R^{63} are independently hydrogen, fluoro or $-C(O)NH_2$.

44. (New) The compound of claim 2, wherein X is $=N-$.

45. (New) The compound of claim 2, wherein G is $-CH(R^{64})-C(R^{65}R^{66})-$; wherein R^{64} , R^{65} , R^{66} are independently hydrogen, F, methyl, $-CH_2F$, $-CHF_2$, CF_3 or cyclopropyl or R^{65} , R^{66} form together cyclopropyl.

46. (New) The compound of claim 2, wherein G is $-CH_2-CH_2-$.

47. (New) The compound of claim 2, wherein D is $-CH_2-$, $-CF_2-$, $-CH(CH_3)-$, $-C(CH_3)_2-$ or D^1-D^2 , where D^1 and D^2 are independently $-CH_2-$, $-CF_2-$, $-CH(CH_3)-$ or $-C(CH_3)_2-$ and wherein D^2 is optionally $-CH_2-NH-$.


48. (New) The compound according to claim 47, wherein D is $-CH_2-$, $-CH(CH_3)-$, $-CH_2-CH_2-$, $-CH_2-CF_2$ or $-CH_2-CH_2-NH-$.

49. (New) The compound of claim 2, wherein -E is selected from the group consisting of a heterocycle containing up to three heteroatoms, which are the same or different and selected from the group consisting of $-O-$, $-N=$, $-N(O)-$ and $-NH-$; and heterobicycle containing up to three heteroatoms, which are the same or different and selected from the group consisting of $-O-$, $-N=$, and $-NH-$; and wherein E is optionally substituted with up to two substituents which are the same or different and selected from the group consisting of CN, F, Cl, C_{1-4} alkyl, OH, $O-C_{1-4}$

alkyl, NH_2 , NH-C_{1-4} alkyl, $\text{N(C}_{1-4}\text{ alkyl)}_2$, C(O)NH_2 , C(O)NH-C_{1-4} alkyl, and $\text{C(O)N(C}_{1-4}\text{ alkyl)}_2$, wherein each C_{1-4} alkyl is optionally substituted with one or more substituents independently selected from OH and F.

50. (New) The compound according to claim 49, wherein -E is pyridine, benzimidazole, indazole, quinoline, isoquinoline, pyridine-(N)-oxide, benzothiophene, indole, azaindole, benzofuran, benzisoxazole, benzoxazole, benzothiazole.

51. (New) The compound of claim 2, wherein -E is selected from the group consisting of



T and V are independently =CH-, =CR⁷¹-, =N- or =N(O)-;

U is -NH-, -NR⁷²-, -O-, or -S-, wherein

R⁶⁷, R⁶⁸, R⁶⁹, R⁷⁰, R⁷¹ are independently selected from the group consisting of
hydrogen;

C₃₋₆ cycloalkyl;

E⁶;

E⁷;

halogen;

CN;

-N(R⁷³R⁷⁴);

-OH; and

-COOR⁷⁵ or -C(O)NR⁷⁶R⁷⁷;

and wherein R⁷², R⁷³, R⁷⁴, R⁷⁵, R⁷⁶, R⁷⁷ are independently
hydrogen;

C₁₋₄ alkyl; or

-C(O)-C₁₋₄ alkyl;

E⁶ is selected from the group consisting of C₁₋₆ alkyl; -O-C₁₋₆ alkyl; and
-N(R⁷⁸)-C₁₋₆ alkyl, wherein the C₁₋₆ alkyl group is optionally substituted with one or more of
halogen;

CN;

-N(R⁷⁹R⁸⁰);

phenyl, optionally substituted with chloro;

heterocycle containing up to 4 heteroatoms, which are the same or different and
selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-, -N=, -N(O)= and
-N(R⁸¹)-, optionally substituted with chloro;

and/or E⁶ is optionally interrupted by one or more of oxygen;

and wherein R⁷⁸, R⁷⁹, R⁸⁰, R⁸¹ are independently hydrogen, C₁₋₄alkyl;

E⁷ is selected from the group consisting of E⁸; -O-E⁸; -N(R⁸²)-E⁸; and -C(O)-E⁸, wherein E⁸ is
phenyl or heterocycle containing up to 4 heteroatoms, which are the same or different and
selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-, -N=, -N(O)= and -N(R⁸³)-; and
wherein E⁸ is optionally substituted with chloro or -N(R⁸⁴R⁸⁵);

and wherein R^{82} , R^{83} , R^{84} , R^{85} are independently hydrogen or C_{1-4} alkyl.

52. (New) The compound according to claim 51, wherein R^{67} , R^{68} , R^{69} , R^{70} , R^{71} are independently selected from the group consisting of hydrogen, fluoro, chloro, cyano, phenyl, chlorophenyl, methyl, methoxy, amino, monomethyl amino, dimethyl amino, pyrrolyl, diazoly, triazolyl, and tetrazolyl.

53. (New) The compound of claim 3, wherein R^1 is hydrogen.

54. (New) The compound of claim 3, wherein R^2 is hydrogen, chloro, $-CH_3$, $-CH_2-CH_3$, $-CH_2-CH_2-CH_3$, $-CH_2F$, $-CHF_2$ or $-CN$.

55. (New) The compound of claim 3, wherein R^3 is hydrogen.

56. (New) The compound of claim 3, wherein A^1 is a heterocycle containing up to 4 heteroatoms, which are the same or different and selected from the group consisting of $-O-$, $-S-$, $-S(O)-$, $-S(O)_2-$, $-N=$, $-N(O)=$ and $-N(R^4)-$, wherein R^4 has the meaning as indicated in claim 3.

57. (New) The compound according to claim 56, wherein A^1 is selected from the group consisting of pyridine, pyridine-N oxide, piperidine, morpholine, and pyrrolidine.

58. (New) The compound of claim 3, wherein R^4 is a bond, $-COOC_{1-4}$ alkyl, methyl, ethyl, 2-hydroxyethyl, $-COOH$, $-CH_2-COOH$, $-CH_2-COO-C_{1-4}$ alkyl or cyclopropylmethyl and wherein A^1 is optionally substituted with up to 4 F.

59. (New) The compound of claim 3, wherein B is $-Y-Z-$.

60. (New) The compound of claim 3, wherein Y is a bond, $-O-$, $-NH-$, $-S(O)_2-$ or $-C(O)-$.

61. (New) The compound of claim 3, wherein Z is $-C(R^{60}R^{61})-$ or $-C(R^{60}R^{61})-C(R^{62}R^{63})-$, wherein

R^{60} , R^{61} , R^{62} , R^{63} are independently hydrogen, $-C(O)NH_2$, $-COOH$, $-CH_2-COOH$, $-CH_2-C(O)NH_2$, fluoro, methyl, cyclopropyl or

R⁶⁰ and R⁶¹ form a cyclopropyl ring or
R⁶² and R⁶³ form a cyclopropyl ring or
R⁶⁰ and R⁶² form a cyclopropyl or cyclobutyl ring.

62. (New) The compound according to claim 61, wherein R⁶⁰, R⁶¹, R⁶², R⁶³ are independently hydrogen, fluoro or -C(O)NH₂.

63. (New) The compound of claim 3, wherein X is =N-.

64. (New) The compound of claim 3, wherein G is -CH(R⁶⁴)-C(R⁶⁵R⁶⁶)-; wherein R⁶⁴, R⁶⁵, R⁶⁶ are independently hydrogen, F, methyl, -CH₂F, -CHF₂, CF₃ or cyclopropyl or R⁶⁵, R⁶⁶ form together cyclopropyl.

65. (New) The compound of claim 3, wherein G is -CH₂-CH₂-.


66. (New) The compound of claim 3, wherein D is -CH₂-, -CF₂-, -CH(CH₃)-, -C(CH₃)₂- or D¹-D², where D¹ and D² are independently -CH₂-, -CF₂-, -CH(CH₃)- or -C(CH₃)₂- and wherein D² is optionally -CH₂-NH-.

67. (New) A compound according to claim 66, wherein D is -CH₂-, -CH(CH₃)-, -CH₂-CH₂-, -CH₂-CF₂ or -CH₂-CH₂-NH-.

68. (New) The compound of claim 3, wherein -E is selected from the group consisting of phenyl; heterocycle containing up to three heteroatoms, which are the same or different and selected from the group consisting of -O-, -N=, -N(O)- and -NH-; and heterobicycle containing up to three heteroatoms, which are the same or different and selected from the group consisting of -O-, -N=, and -NH-; and wherein E is optionally substituted with up to two substituents which are the same or different and selected from the group consisting of CN, F, Cl, C₁₋₄ alkyl, OH, O-C₁₋₄ alkyl, NH₂, NH-C₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, C(O)NH₂, C(O)NH-C₁₋₄ alkyl, and C(O)N(C₁₋₄ alkyl)₂, wherein each C₁₋₄ alkyl is optionally substituted with one or more substituents independently selected from OH and F.

69. (New) The compound according to claim 68, wherein -E is phenyl, pyridine, benzimidazole, indazole, quinoline, isoquinoline, pyridine-(N)-oxide, benzothiophene, indole, azaindole, benzofuran, benzisoxazole, benzoxazole, benzothiazole.

70. (New) The compound of claim 3, wherein -E is selected from the group consisting of



wherein

T and V are independently =CH-, =CR⁷¹-, =N- or =N(O)-;

U is -NH-, -NR⁷²-, -O-, or -S-, wherein

R⁶⁷, R⁶⁸, R⁶⁹, R⁷⁰, R⁷¹ are independently selected from the group consisting of

hydrogen;

C₃₋₆ cycloalkyl;

E⁶;

E⁷;

halogen;

CN;

-N(R⁷³R⁷⁴);

-OH; and

-COOR⁷⁵ or -C(O)NR⁷⁶R⁷⁷;

and wherein R⁷², R⁷³, R⁷⁴, R⁷⁵, R⁷⁶, R⁷⁷ are independently

hydrogen;

C₁₋₄ alkyl; or

-C(O)-C₁₋₄ alkyl;

E⁶ is selected from the group consisting of C₁₋₆ alkyl; -O-C₁₋₆ alkyl; and -N(R⁷⁸)-C₁₋₆ alkyl, wherein the C₁₋₆ alkyl group is optionally substituted with one or more of

halogen;

CN;

-N(R⁷⁹R⁸⁰);

phenyl, optionally substituted with chloro;

heterocycle containing up to 4 heteroatoms, which are the same or different and selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-, -N=, -N(O)= and -N(R⁸¹)-, optionally substituted with chloro;

and/or E⁶ is optionally interrupted by one or more of oxygen;

and wherein R⁷⁸, R⁷⁹, R⁸⁰, R⁸¹ are independently hydrogen, C₁₋₄alkyl;

E⁷ is selected from the group consisting of E⁸; -O-E⁸; -N(R⁸²)-E⁸; and -C(O)-E⁸, wherein E⁸ is phenyl or heterocycle containing up to 4 heteroatoms, which are the same or different and selected from the group consisting of -O-, -S-, -S(O)-, -S(O₂)-, -N=, -N(O)= and -N(R⁸³)-; and wherein E⁸ is optionally substituted with chloro or -N(R⁸⁴R⁸⁵);

and wherein R⁸², R⁸³, R⁸⁴, R⁸⁵ are independently hydrogen or C₁₋₄ alkyl.

71. (New) The compound according to claim 70, wherein R^{67} , R^{68} , R^{69} , R^{70} , R^{71} are independently selected from the group consisting of hydrogen, fluoro, chloro, cyano, phenyl, chlorophenyl, methyl, methoxy, amino, monomethyl amino, dimethyl amino, pyrrolyl, diazoly, triazoly, and tetrazoly.

72. (New) A prodrug of a compound according to claim 1.

73. (New) A prodrug of a compound according to claim 2.

74. (New) A prodrug of a compound according to claim 3.

75. (New) A pharmaceutical composition comprising at least one prodrug of claim 72 and a pharmaceutically acceptable carrier.

76. (New) A pharmaceutical composition comprising at least one prodrug of claim 73 and a pharmaceutically acceptable carrier.

77. (New) A pharmaceutical composition comprising at least one prodrug of claim 74 and a pharmaceutically acceptable carrier.

78. (New) A method for the treatment or prophylaxis of thromboembolism, thrombosis, arteriosclerosis, unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, or reocclusion or restenosis of recanalized vessels, comprising administering to a patient a composition comprising the prodrug of claim 72.

79. (New) The prodrug of claim 72, wherein an amino group in Formula (I) is acylated, alkylated, or phosphorylated to form said prodrug.

80. (New) The prodrug of claim 73, wherein an amino group in Formula (I) is acylated, alkylated, or phosphorylated to form said prodrug.

81. (New) The prodrug of claim 74, wherein an amino group in Formula (I) is acylated, alkylated, or phosphorylated to form said prodrug.